Odevixibat — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-02-15 in 3mo
ESTIMATED |
READOUT
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Phase 3 · Alagille Syndrome |
Albireo, an Ipsen Company | Odevixibat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|